These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 8018139

  • 1. Evaluating drugs after their approval for clinical use.
    Ray WA, Griffin MR, Avorn J.
    N Engl J Med; 1993 Dec 30; 329(27):2029-32. PubMed ID: 8018139
    [No Abstract] [Full Text] [Related]

  • 2. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J, Friedlin J, Ryan P.
    Arch Intern Med; 2011 May 23; 171(10):944-6. PubMed ID: 21606101
    [No Abstract] [Full Text] [Related]

  • 3. Invited commentary--prescription drug label adverse events: a call for prioritization: comment on "A quantitative analysis of adverse events and 'overwarning' in drug labeling".
    Cheng C, Guglielmo BJ.
    Arch Intern Med; 2011 May 23; 171(10):946-7. PubMed ID: 21606102
    [No Abstract] [Full Text] [Related]

  • 4. Consumer groups look to improve adverse event reporting systems.
    Vastag B.
    J Natl Cancer Inst; 2005 Dec 21; 97(24):1804-5. PubMed ID: 16368939
    [No Abstract] [Full Text] [Related]

  • 5. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL.
    J Natl Cancer Inst; 2005 Jun 15; 97(12):872-3. PubMed ID: 15956645
    [No Abstract] [Full Text] [Related]

  • 6. Adverse drug reaction reporting.
    Bosco LA.
    Am J Gastroenterol; 1987 Apr 15; 82(4):356-7. PubMed ID: 3565343
    [No Abstract] [Full Text] [Related]

  • 7. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT.
    Food Drug Law J; 2007 Apr 15; 62(3):559-72. PubMed ID: 17915397
    [No Abstract] [Full Text] [Related]

  • 8. The risks of pharmacological therapy for insomnia (part 1): update for the clinical nurse specialist.
    O'Malley P.
    Clin Nurse Spec; 2007 Apr 15; 21(4):188-90. PubMed ID: 17622806
    [No Abstract] [Full Text] [Related]

  • 9. The role of databases in drug postmarketing surveillance.
    Rodriguez EM, Staffa JA, Graham DJ.
    Pharmacoepidemiol Drug Saf; 2001 Apr 15; 10(5):407-10. PubMed ID: 11802586
    [Abstract] [Full Text] [Related]

  • 10. FDA guidance document on monitoring delayed adverse events a good first start.
    Williams DA.
    Mol Ther; 2005 Dec 15; 12(6):991-2. PubMed ID: 16271514
    [No Abstract] [Full Text] [Related]

  • 11. The drug safety system conundrum.
    Tiedt TN.
    Food Drug Law J; 2007 Dec 15; 62(3):547-558. PubMed ID: 17915396
    [No Abstract] [Full Text] [Related]

  • 12. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP, Salas M, Delzell E.
    J Clin Pharmacol; 2007 Sep 15; 47(9):1074-86. PubMed ID: 17766697
    [Abstract] [Full Text] [Related]

  • 13. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD, Feigal D.
    Food Drug Law J; 2007 Sep 15; 62(3):529-46. PubMed ID: 17915395
    [No Abstract] [Full Text] [Related]

  • 14. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK, Swartz L.
    Arch Intern Med; 2005 Jun 27; 165(12):1363-9. PubMed ID: 15983284
    [Abstract] [Full Text] [Related]

  • 15. National adverse drug reaction surveillance. 1986.
    Faich GA, Dreis M, Tomita D.
    Arch Intern Med; 1988 Apr 27; 148(4):785-7. PubMed ID: 3355297
    [Abstract] [Full Text] [Related]

  • 16. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL, Hanson A, Guglielmetti TM, Levy K.
    Food Drug Law J; 2007 Apr 27; 62(3):445-72. PubMed ID: 17915388
    [No Abstract] [Full Text] [Related]

  • 17. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA, Brushwood DB.
    J Health Law; 2000 Apr 27; 33(3):383-454. PubMed ID: 11184355
    [Abstract] [Full Text] [Related]

  • 18. Safety in numbers--monitoring risk in approved drugs.
    Okie S.
    N Engl J Med; 2005 Mar 24; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract] [Full Text] [Related]

  • 19. Reporting of adverse drug events: a key to postmarketing drug safety.
    Rheinstein PH.
    Am Fam Physician; 1992 Sep 24; 46(3):873-4. PubMed ID: 1514478
    [No Abstract] [Full Text] [Related]

  • 20. Adverse drug event reporting. Improving the low US reporting rates.
    Edlavitch SA.
    Arch Intern Med; 1988 Jul 24; 148(7):1499-503. PubMed ID: 3382293
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.